BRAF and metastatic melanoma: The next year, the FDA approved encorafenib in combination with binimetinib which is an anti-MEK1/2 protein kinase inhibitor for the treatment of unresectable or metastatic melanoma patients with mutations in BRAF V600E or BRAF V600K based on a Phase III randomized, active-controlled, open-label, multicenter trial (COLUMBUS) (16).